^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    milatuzumab (IMMU-115)

    i
    Other names: IMMU-115, hLL1-DOX, hLL1, humanised anti-CD74, hCD74
    Associations

    News

    Trials
    Company:
    Gilead
    Drug class:
    CD74 inhibitor
    Associations

    News

    Trials
    7ms
    Single-cell RNA sequencing analysis revealed the immunosuppressive remodeling of tumor-associated macrophages mediated by the MIF-CD74 axis in gastric cancer. (PubMed, Sci Rep)
    Crucially, Milatuzumab, a CD74-targeting antibody, reversed MIF-induced TAM immunosuppression in vitro. Our research provides a comprehensive map of GC-TAM heterogeneity; reveals that the MIF-CD74 axis is a key driver of TAM-mediated immune suppression; and proposes that CD74 blockade is a new therapeutic strategy for GC.
    Journal • IO biomarker
    |
    CD74 (CD74 Molecule) • IDO1 (Indoleamine 2,3-dioxygenase 1) • APOE (Apolipoprotein E) • POLG2 (DNA Polymerase Gamma 2, Accessory Subunit) • SKAP1 (Src Kinase Associated Phosphoprotein 1)
    |
    milatuzumab (IMMU-115)
    over2years
    A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models. (PubMed, Exp Hematol Oncol)
    Targeting CD74 with 74bbz CAR-T cells represents a new cell therapy to provide a potent and durable and anti-MCL activity.
    Preclinical • Journal • CAR T-Cell Therapy • IO biomarker
    |
    CD74 (CD74 Molecule) • MIF (Macrophage Migration Inhibitory Factor)
    |
    Imbruvica (ibrutinib) • milatuzumab (IMMU-115)